# Nivolumab With Chemotherapy in Refractory MDS

> **NCT03259516** · PHASE1,PHASE2 · TERMINATED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Azacitidine
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** all trans retinoic acid
- **DRUG:** Sildenafil
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT03259516
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-25
- **Primary completion:** 2018-12-25
- **Final completion:** 2018-12-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow recruitment rate
- **Last updated:** 2019-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259516, "Nivolumab With Chemotherapy in Refractory MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03259516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*